Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now X
Company Description (as filed with the SEC)
We are a specialty pharmaceutical company developing and planning to commercialize proprietary, abuse-deterrent oral products for the treatment of pain and in other indications. Using our proprietary technology platform, we have developed a pipeline of clinical-stage, opioid-based product candidates in tablet form that are specifically designed to deter abuse by physical and chemical manipulation while also providing the ability to tailor the release of the active pharmaceutical ingredient ("API"). Our lead product candidate, Egalet-001, is an abuse-deterrent, extended-release, oral morphine formulation in development for the treatment of moderate to severe pain. We have initiated our pivotal bioequivalence clinical trials for Egalet-001 in the first quarter of 2014 and plan to submit a new drug application ("NDA") to the U.S. Food and Drug Administration ("FDA") in the fourth quarter of 2014. ... More ...
Where does EGLT fit in the risk graph?
|Annual EPS Est:||$999|
|Quarterly EPS Est:||-0.71|